Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives $56.00 Average Price Target from Brokerages

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have earned a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $60.8571.

A number of brokerages have weighed in on KNSA. Citigroup lifted their target price on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Tuesday, April 21st. Wells Fargo & Company lifted their target price on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Wednesday, April 29th. Wall Street Zen raised Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research report on Monday. Finally, Jefferies Financial Group lifted their target price on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th.

Kiniksa Pharmaceuticals International Stock Up 4.3%

KNSA opened at $57.62 on Tuesday. The business has a fifty day moving average of $46.40 and a 200 day moving average of $43.20. Kiniksa Pharmaceuticals International has a 52-week low of $24.85 and a 52-week high of $57.72. The stock has a market cap of $4.41 billion, a P/E ratio of 64.02 and a beta of 0.17.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. The company had revenue of $214.27 million during the quarter, compared to analysts’ expectations of $206.11 million. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.Kiniksa Pharmaceuticals International’s revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.11 EPS. Equities analysts anticipate that Kiniksa Pharmaceuticals International will post 1.22 EPS for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, Director Barry D. Quart sold 13,099 shares of Kiniksa Pharmaceuticals International stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total transaction of $656,259.90. Following the completion of the sale, the director directly owned 12,546 shares of the company’s stock, valued at $628,554.60. The trade was a 51.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ross Moat sold 1,703 shares of Kiniksa Pharmaceuticals International stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $46.69, for a total value of $79,513.07. Following the sale, the chief operating officer directly owned 12,029 shares of the company’s stock, valued at approximately $561,634.01. This trade represents a 12.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 618,124 shares of company stock valued at $31,923,594. Company insiders own 53.48% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Rubric Capital Management LP raised its position in shares of Kiniksa Pharmaceuticals International by 2.3% in the 3rd quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock worth $155,320,000 after acquiring an additional 90,194 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Kiniksa Pharmaceuticals International by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock worth $128,409,000 after acquiring an additional 49,802 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Kiniksa Pharmaceuticals International by 45.3% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock worth $41,481,000 after acquiring an additional 332,846 shares in the last quarter. Qube Research & Technologies Ltd raised its position in shares of Kiniksa Pharmaceuticals International by 277.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after acquiring an additional 653,236 shares in the last quarter. Finally, Millennium Management LLC raised its position in shares of Kiniksa Pharmaceuticals International by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after acquiring an additional 67,452 shares in the last quarter. 53.95% of the stock is owned by institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.